Process for antibody directed enzyme prodrug therapy
US5660829A · kind A · utility
26Cited by
2References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 16, 1995 |
| Grant date | Aug 26, 1997 |
| Priority date | — |
| Expiry date | May 16, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C311/51
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalysed reactions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.